





Detection and Confirmation of Braf-V600E and V600K Mutation

Gold Standard Accuracy  Verifiable Results Format  Multiplexed High Throughput  Rapid TAT
 Cost-Effective Testing for late stage Melanoma, Non-small Cell Lung Carcinoma and Thyroid Cancer



Braf Tumorplex™ (For Solid Tumors)

FFPE Sample



DNA extraction from
2 FFPE slides



PCR




Allele Specific Multiplex
Sequencing



Results

Key Features

- ✓ Detection and confirmation of V600E/K mutations
- ✓ Highest sensitivity Mutant: Wild >1:100,000 vs 1:1000
- ✓ Wild Type as internal control without suppression
- ✓ No need for tumor cell enrichment = cost savings
- ✓ Small sample volume (FFPE slides = 2)
- ✓ LOD: 15 copies vs 4000 copies



References:

1. Vinayagamoorthy, T., Zhang, D., Ye, F., Vinayagamoorthy, D., Roger Hodgkinson. Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests. 2017. Journal of Solid Tumors. Vol 7, No.2
2. Jacob Yo, Katie S.L. Hay, Dilanthi Vinayagamoorthy, Danielle Maryanski, Mark Carter, Joseph Wiegel, Thuraiayah Vinayagamoorthy. Detection of BRAF mutations from solid tumors using Tumorplex™ technology. MethodsX 2(2015)316-322

CONFIDENTIAL -- NOT FOR DISTRIBUTION This test has not been reviewed or cleared by the FDA